Skip to content
PeptideHormone

Selank

A synthetic anxiolytic/nootropic peptide derived from tuftsin.

Research peptideLimitedUnapproved

An endogenous fragment given a longer life by synthesis. The neuropeptide biology is real; the human evidence is thin, and mostly from one research tradition.

Identity

Class
Synthetic heptapeptide (tuftsin analog)
Source
Synthetic; based on the immunopeptide tuftsin
Receptor
No single established receptor; effects on GABA/serotonin and immune signaling proposed

Key properties

Evidence floorPreclinicalREF1PRE1
Molecular weight
≈ 751.9 Da
REF
Half-life (native)
Minutes in plasma (CNS effects outlast)
PRE

Approximate values for the native hormone; engineered analogs are often deliberately larger and far longer-acting. Each figure carries its own provenance tier, and the floor is the weakest of them - the Standard.

Mechanism

Selank is a synthetic heptapeptide based on the immune-active fragment tuftsin, developed (largely in Russia) as an anxiolytic and nootropic. Proposed effects touch GABAergic, serotonergic, and immune signaling, but well-controlled independent human evidence is limited.

Reference notes

  • Derived from tuftsin, an endogenous immunomodulatory peptide fragment.
  • Developed primarily outside large international trial programs; independent evidence is limited.
  • Mechanism is proposed across several systems rather than firmly established.

Regulatory status

United States · reviewed September 2026
UnapprovedSelank is sold outside the approved-drug system as research-use-only material, with no FDA approval for human use.
Basis
Approved as an anxiolytic in Russia; no FDA approval or US trials.

Status describes the molecule as a drug substance under US law and is an editorial reading of the public record — approvals, trial registrations, and the FDA 503A bulk-substances list. It is not legal advice and it changes; the review date above is the last time the table was checked. Other jurisdictions are noted only where they differ materially.

Common questions

What is Selank?
A synthetic anxiolytic/nootropic peptide derived from tuftsin. Structurally it is Synthetic heptapeptide (tuftsin analog).
How does Selank work?
Selank is a synthetic heptapeptide based on the immune-active fragment tuftsin, developed (largely in Russia) as an anxiolytic and nootropic. Proposed effects touch GABAergic, serotonergic, and immune signaling, but well-controlled independent human evidence is limited.
How strong is the evidence for Selank?
PeptideHormone grades Selank at the "Limited" evidence tier — the evidence is sparse, older, or mostly community-reported. It is catalogued as a community research peptide outside the approved-drug system, and the tier is an editorial judgment about the public literature that can change as the science does.
What is the half-life of Selank?
The reported circulating half-life of Selank is Minutes in plasma (CNS effects outlast).
Is Selank FDA-approved?
No — as of September 2026, Selank is sold outside the approved-drug system as research-use-only material, with no FDA approval for human use. Approved as an anxiolytic in Russia; no FDA approval or US trials. Status is US-centric and can change; check the FDA record for the current position.

In the literature

Live registry counts · retrieved
Registered trialsREF
0
  • Ph 10
  • Ph 20
  • Ph 30
  • Ph 40
Open on ClinicalTrials.gov
PubMed recordsREF
68
Since 20222 · 3%
Open on PubMed

Searched as Selank. Counts are search hits from the primary registries, not a curated set and not a grade – a measure of how much work exists on Selank, not how it turned out.

Selected literature

Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.

  1. 1.Tuftsin - Properties and Analogs · Current medicinal chemistry, 2017 · PMID 28745220

External references

Selank in the public knowledge graph — the same entity resolved across the authoritative chemistry and protein databases.